GLP-1 drugs

ResMed's stock faces potential risks as GLP-1 drugs, approved for weight loss and diabetes, may be prescribed for other...

Eli Lilly & Co. faces backlash over new pricing for its weight-loss drug Zepbound, as costs rise for many...

Novo Nordisk is set to report its second-quarter results on Wednesday, with a FactSet poll predicting a 10% rise...

In the competitive world of weight-loss drugs, Eli Lilly and Novo Nordisk currently dominate the market with injectable GLP-1s...

Krispy Kreme's stock surged 5.6% after Truist upgraded it to a "buy" rating, citing three key points: the underappreciated...

In a recent investigation led by U.S. Senator Bernie Sanders, Novo Nordisk has blamed middlemen in the U.S. healthcare...

New research reveals that over 76% of young adults prescribed GLP-1 drugs last year were women, raising concerns about...

Hims & Hers Health Inc.'s stock soars over 30% after announcing plans to offer compounded GLP-1 drugs, similar to...

Lead: Novo Nordisk's stock skyrockets to a record high as the Danish drugmaker unveils groundbreaking next-generation drugs, solidifying its...

Lead: A groundbreaking trial by Novo Nordisk reveals that its weight-loss drug, Ozempic, reduces the risk of kidney disease-related...